Abstract
The role of PPARgamma in tumorigenesis is controversial. In this article, we review and analyze literature from the past decade that highlights the potential proneoplastic activity of PPARgamma. We discuss the following five aspects of the nuclear hormone receptor and its agonists: (1) relative expression of PPARgamma in human tumor versus normal tissues; (2) receptor-dependent proneoplastic effects; (3) impact of PPARgamma and its agonists on tumors in animal models; (4) clinical trials of thiazolidinediones (TZDs) in human malignancies; (5) TZDs as chemopreventive agents in epidemiology studies. The focus is placed on the most relevant in vivo animal models and human data. In vitro cell line studies are included only when the effects are shown to be dependent on the PPARgamma receptor.